Clinical Trial Update: Efficacy and Safety Assessment of NIlotinib in CML Patients With Suboptimal Response on Imatinib Therapy [Phase 4]

View source ↗

Summary

Phase 4 trial assessing the efficacy and safety of nilotinib in chronic myeloid leukemia patients with suboptimal response to imatinib was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Myeloid Leukemia

Drugs mentioned

• Nilotinib (nilotinib)

Snippet

Sponsor: King Abdullah International Medical Research Center | Conditions: Myeloid Leukemia, Chronic | Phase 4 | Status: TERMINATED